CSU vaccine research advances, groundwork begins to develop coronavirus vaccine for the next pandemic
Researchers aim to create a vaccine candidate that would protect people from a spectrum of coronaviruses.
Researchers aim to create a vaccine candidate that would protect people from a spectrum of coronaviruses.
Dr. John Eisenach was inspired by a mentor to create the Colorado COVID-19 Convalescent Plasma Project Consortium.
Colorado State University’s spending on research activities reached a record $407 million for fiscal year 2020, a 2% increase over last year.
Since the start of the coronavirus pandemic, Colorado State University has received more than $16 million in funding for COVID-19 research projects.
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
Sen. Cory Gardner was on campus to learn about CSU's work in testing, senior care facility surveillance and vaccine development.
A team of CSU researchers has entered into an agreement with the Biomedical Advanced Research and Development Authority to further develop a novel process that has the potential to inactivate the SARS-CoV-2 virus.
The research team used existing technologies to treat nine plasma and three whole-blood products.
Using a manufacturing platform developed to prevent the transmission of disease during blood transfusions, IDRC staffers are working with the faculty of several departments at CSU to test an internally developed vaccine candidate dubbed SolaVAX.
Over the last decade, there have been advances in manufacturing and in strategies to rapidly produce a vaccine.